Drug interactions in dentistry

Moore, 1999, Adverse drug interactions in dental practice: professional and educational implications, JADA, 130, 47 Michalets, 1998, Update: clinically significant cytochrome P-450 drug interactions, Pharmacotherapy, 18, 84, 10.1002/j.1875-9114.1998.tb03830.x Cupp, 1998, Cytochrome P450: new nomenclature and clinical implications, Am Fam Physician, 57, 107 Venkatakrishnan, 2000, Effects of the antifungal agents on oxidative drug metabolism: clinical relevance, Clin Pharmacokinet, 38, 111, 10.2165/00003088-200038020-00002 Indiana University Antoniou, 2002, Interactions between recreational drugs and antiretroviral agents, Ann Pharmacother, 36, 1596, 10.1345/aph.1A447 Piscitelli, 2000, Indinavir concentrations and St. John’s wort, Lancet, 355, 547, 10.1016/S0140-6736(99)05712-8 Dresser, 2000, Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition, Clin Pharmacokinet, 38, 41, 10.2165/00003088-200038010-00003 Bailey, 1998, Grapefruit juice-drug interactions, Br J Clin Pharmacol, 46, 101, 10.1046/j.1365-2125.1998.00764.x Bjornsson, 2003, The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective, J Clin Pharmacol, 43, 443, 10.1177/0091270003252519 Bailey, 2003, Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice, Clin Pharmacol Ther, 73, 529, 10.1016/S0009-9236(03)00051-1 Bailey, 1991, Interaction of citrus juices with felodipine and nifedipine, Lancet, 337, 268, 10.1016/0140-6736(91)90872-M Lown, 1997, Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression, J Clin Invest, 99, 2545, 10.1172/JCI119439 Jackson, 2002, Inhalation and enteral conscious sedation for the adult dental patient, Dent Clin North Am, 46, 781, 10.1016/S0011-8532(02)00029-0 Hersh, 1999, Adverse drug interactions in dental practice: interactions involving antibiotics, part II of a series, JADA, 130, 236 Moore, 1999, Adverse drug interactions in dental practice: interactions associated with local anesthetics, sedatives and anxiolytics, part IV of a series, JADA, 130, 541 Olkkola, 1993, A potentially hazardous interaction between erythromycin and midazolam, Clin Pharmacol Ther, 53, 298, 10.1038/clpt.1993.25 Mattila, 1993, Oral single doses of erythromycin and roxithromycin may increase the effects of midazolam on human performance, Pharmacol Toxicol, 73, 180, 10.1111/j.1600-0773.1993.tb01560.x Yasui, 1998, Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam, Psychopharmacology (Berl), 139, 269, 10.1007/s002130050715 Olkkola, 1994, Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole, Clin Pharmacol Ther, 55, 481, 10.1038/clpt.1994.60 Varhe, 1994, Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole, Clin Pharmacol Ther, 56, 601, 10.1038/clpt.1994.184 Greenblatt, 2000, Alprazolamritonavir interaction: implications for product labeling, Clin Pharmacol Ther, 67, 335, 10.1067/mcp.2000.105757 von Moltke, 1996, Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole, J Pharmacol Exp Ther, 276, 370 Goho, 2001, Oral midazolam-grapefruit juice drug interaction, Pediatr Dent, 23, 365 Ozdemir, 1998, Interaction between grapefruit juice and diazepam in humans, Eur J Drug Metab Pharmacokinet, 23, 55, 10.1007/BF03189827 Beaver, 1981, Aspirin and acetaminophen as constituents of analgesic combinations, Arch Intern Med, 141, 293, 10.1001/archinte.1981.00340030025006 McQuay, 2003, Meta-analysis of single dose oral tramadol plus acetaminophen in acute postoperative pain, Eur J Anaesthesiol, 20, 19 Desmeules, 1991, Impact of environmental and genetic factors on codeine analgesia, Eur J Clin Pharmacol, 41, 23, 10.1007/BF00280101 Lee, 1993, Tramadol: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states, Drugs, 46, 313, 10.2165/00003495-199346020-00008 Garrido, 2003, Pharmacokinetic/pharmacodynamic modeling of the antinociceptive effects of (+)-tramadol in the rat: role of cytochrome P450 2D activity, J Pharmacol Exp Ther, 305, 710, 10.1124/jpet.102.047779 Orlando, 2003, Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function, Br J Clin Pharmacol, 55, 86, 10.1046/j.1365-2125.2003.01718.x Hiroi, 1995, Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms, J Pharmacol Exp Ther, 272, 939 Hersh, 1991, Local anesthetic mortality: report of case, ASDC J Dent Child, 58, 489 Moore, 1992, Preventing local anesthesia toxicity, JADA, 123, 60 Cooper, 1983, New peripherally-acting analgesic agents, Annu Rev Pharmacol Toxicol, 23, 617, 10.1146/annurev.pa.23.040183.003153 Hersh, 2000, Over-the-counter analgesics and antipyretics: a critical assessment, Clin Ther, 22, 500, 10.1016/S0149-2918(00)80043-0 Kirchheiner, 2002, Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2, Clin Pharmacol Ther, 72, 62, 10.1067/mcp.2002.125726 Brenner, 2003, Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib, Clin Pharmacokinet, 42, 283, 10.2165/00003088-200342030-00003 Kirchheiner, 2003, Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans, Br J Clin Pharmacol, 55, 51, 10.1046/j.1365-2125.2003.01712.x Tracy, 1997, Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation, Eur J Clin Pharmacol, 52, 293, 10.1007/s002280050293 Jones, 2002, Over-the-counter analgesics: a toxicology perspective, Am J Ther, 9, 245, 10.1097/00045391-200205000-00010 Prescott, 1998, Current status of issues concerning the safety of over-the-counter analgesics and nonsteroidal anti-inflammatory drugs, 1 Rumack, 2002, Acetaminophen hepatotoxicity: the first 35 years, J Toxicol Clin Toxicol, 40, 3, 10.1081/CLT-120002882 Rivera-Penera, 1997, Outcome of acetaminophen overdose in pediatric patients and factors contributing to hepatotoxicity, J Pediatr, 130, 300, 10.1016/S0022-3476(97)70359-7 Haas, 1999, Adverse drug interactions in dental practice: interactions associated with analgesics, part III in a series, JADA, 130, 397 Friedlander, 2003, Alcohol abuse and dependence: psychopathology, medical management and dental implications, JADA, 134, 731 1999, Over-the-counter drug products containing analgesic/antipyretic active ingredients for internal use; required alcohol warning; final rule; compliance date. U.S. Food and Drug Administration, Department of Health and Human Services, Fed Regist, 64, 13066 Slattery, 1996, The complex interaction between ethanol and acetaminophen, Clin Pharmacol Ther, 60, 241, 10.1016/S0009-9236(96)90050-8 Rumack, 1978, Acetaminophen overdose: incidence, diagnosis and management in 416 patients, Pediatrics, 62, 898, 10.1542/peds.62.5S.898 Rumack, 1981, Acetaminophen overdose: 662 cases with evaluation of oral acetylcysteine treatment, Arch Intern Med, 141, 380, 10.1001/archinte.1981.00340030112020 Lyons, 1997, Treatment of acetaminophen overdosage with N-acetylcysteine, N Engl J Med, 296, 174 Dart, 2000, Treatment of pain of fever with paracetamol (acetaminophen) in the alcoholic patient: a systemic review, Am J Ther, 7, 123, 10.1097/00045391-200007020-00009 U.S. Food and Drug Administration Trummel, 1998, Antiinflammatory drugs, 297 Villikka, 2001, Effect of methylprednisolone on CYP3A4-mediated drug metabolism in vivo, Eur J Clin Pharmacol, 57, 457, 10.1007/s002280100340 McCune, 2000, In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone, Clin Pharmacol Ther, 68, 356, 10.1067/mcp.2000.110215 LaForce, 1983, Inhibition of methylprednisolone elimination in the presence of erythromycin therapy, J Allergy Clin Immunol, 72, 34, 10.1016/0091-6749(83)90049-0 Fost, 1999, Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy, J Allergy Clin Immunol, 103, 1031, 10.1016/S0091-6749(99)70175-2 Glynn, 1986, Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion, Clin Pharmacol Ther, 39, 654, 10.1038/clpt.1986.114 Varis, 1998, Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole, Clin Pharmacol Ther, 64, 363, 10.1016/S0009-9236(98)90066-2 Booker, 2002, Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers, Clin Pharmacol Ther, 72, 370, 10.1067/mcp.2002.127944 Varis, 2000, Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone, Clin Pharmacol Ther, 67, 215, 10.1067/mcp.2000.104611 Varis, 2000, Grapefruit juice can increase the plasma concentrations of oral methylprednisolone, Eur J Clin Pharmacol, 56, 489, 10.1007/s002280000171 Loeffler, 1992, Oral benzodiazepines and conscious sedation: a review, J Oral Maxillofac Surg, 50, 989, 10.1016/0278-2391(92)90061-4 Chan, 1994, Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model, Clin Pharmacol Ther, 56, 286, 10.1038/clpt.1994.139 Wenzel, 2002, Do butalbital-containing products have a role in the management of migraine?, Pharmacotherapy, 22, 1029, 10.1592/phco.22.12.1029.33595 Muller, 2002, In vitro antimicrobial susceptibility of oral strains of Actinobacillus actinomycetemcomitans to seven antibiotics, J Clin Periodontol, 29, 736, 10.1034/j.1600-051X.2002.290810.x Slots, 2002, Selection of antimicrobial agents in periodontal therapy, J Periodontal Res, 37, 389, 10.1034/j.1600-0765.2002.00004.x Slots, 1990, Prevalence and antimicrobial susceptibility of Enterobacteriaceae, Pseudomonadaceae and Acinetobacter in human periodontitis, Oral Microbiol Immunol, 5, 149, 10.1111/j.1399-302X.1990.tb00413.x Batty, 1995, The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects, Br J Clin Pharmacol, 39, 305, 10.1111/j.1365-2125.1995.tb04453.x Wijnands, 1986, The influence of quinolone derivatives on theophylline clearance, Br J Clin Pharmacol, 22, 677, 10.1111/j.1365-2125.1986.tb02957.x Raaska, 2000, Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia, Eur J Clin Pharmacol, 56, 585, 10.1007/s002280000192 Markowitz, 1997, Fluroquinolone inhibition of clozapine metabolism, Am J Psychiatry, 153, 881 Perkins, 2002, Predictors of noncompliance in patients with schizophrenia, J Clin Psychiatry, 63, 1121, 10.4088/JCP.v63n1206 Ciancio, 2001, Antibiotics in periodontal therapy, 113 Baumgartner, 2001, Antibiotics in endodontic therapy, 143 Peterson, 2001, Antibiotics for oral and maxillofacial infections, 157 Beikler, 2001, Antimicrobials in implant dentistry, 195 Kazmier, 1976, A significant interaction between metronidazole and warfarin, Mayo Clin Proc, 51, 782 O’Reilly, 1976, The stereoselective interaction of warfarin and metronidazole in man, N Eng J Med, 295, 354, 10.1056/NEJM197608122950702 Blyden, 1988, Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam, J Clin Pharmacol, 28, 240, 10.1002/j.1552-4604.1988.tb03139.x 2003, Kapseals dilantin (extended phenytoin sodium capsules, USP), 2531 Montgomery, 1998, Antibacterial antibiotics, 496 Montgomery, 1998, Antimicrobial agents in the prevention and treatment of infection, 634 Honig, 1993, Effect of erythromycin, clarithromycin and azithromycin on pharmacokinetics of terfenadine, Clin Pharmacol Ther, 53, 161 Matitila, 1994, Azithromycin does not alter the effects of oral midazolam on human performance, Eur J Clin Pharmacol, 47, 49 Harris, 1995, Azithromycin and terfenadine: lack of drug interaction, Clin Pharmacol Ther, 58, 310, 10.1016/0009-9236(95)90247-3 Sanz, 2001, Individual drugs, 33 Honig, 1993, Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin, Clin Pharmacol Ther, 53, 231 Biglin, 1994, Drug-induced torsades de pointes: a possible interaction of terfenadine and erythromycin, Ann Pharmacother, 28, 282, 10.1177/106002809402800226 Kivisto, 1994, Inhibition of terfenadine metabolism: pharmacokinetic and pharmacodynamic consequences, Clin Pharmacokinet, 27, 1, 10.2165/00003088-199427010-00001 Honig, 1993, Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences, JAMA, 269, 1513, 10.1001/jama.1993.03500120051025 Honig, 1993, Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics, J Clin Pharmacol, 33, 1201, 10.1002/j.1552-4604.1993.tb03920.x Goss, 1993, Torsades de pointes associated with astemizole (Hismanal) therapy, Arch Intern Med, 153, 2705, 10.1001/archinte.1993.00410230129016 Lefebvre, 1997, Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole, Br J Clin Pharmacol, 43, 319, 10.1046/j.1365-2125.1997.00548.x Kyrmizakis, 2002, QT prolongation and torsades de pointes associated with concurrent use of cisapride and erythromycin, Am J Otolaryngol, 23, 303, 10.1053/ajot.2002.124543 Piquette, 1999, Torsades de pointes induced by cisapride/clarithromycin interaction, Ann Pharmacother, 33, 22, 10.1345/aph.18107 van Haarst, 1998, The influence of cisapride and clarithromycin on QT intervals in healthy volunteers, Clin Pharmacol Ther, 64, 542, 10.1016/S0009-9236(98)90137-0 Desta, 1999, Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6), Clin Pharmacol Ther, 65, 10, 10.1016/S0009-9236(99)70117-7 Spach, 1991, Rhabdomyolysis associated with lovastatin and erythromycin use, West J Med, 154, 213 Kantola, 1998, Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations, Clin Pharmacol Ther, 64, 177, 10.1016/S0009-9236(98)90151-5 Lees, 1995, Rhabdomyolysis from the coadminsistration of lovastatin and the antifungal agent itraconazole, N Engl J Med, 333, 664, 10.1056/NEJM199509073331015 Neuvonen, 1996, Itraconazole drastically increases plasma concentrations of lovastatin and lovastatic acid, Clin Pharmacol Ther, 60, 54, 10.1016/S0009-9236(96)90167-8 Neuvonen, 1998, Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole, Clin Pharmacol Ther, 63, 332, 10.1016/S0009-9236(98)90165-5 Mazzu, 2000, Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin, Clin Pharmacol Ther, 68, 391, 10.1067/mcp.2000.110537 Bennett, 1997, Musculoskeletal and connective tissue disease, 921 Shaukat, 2003, Simvastatin-fluconazole causing rhabdomyolysis, Ann Pharmacother, 37, 1032, 10.1345/aph.1C467 Liedholm, 1991, Erythromycin-felodipine interaction, DICP, 25, 1007, 10.1177/106002809102500918 Neuvonen, 1995, Itraconazole interacts with felodipine, J Am Acad Dermatol, 33, 134, 10.1016/0190-9622(95)90040-3 Tailor, 1996, Peripheral edema due to nifedipine-itraconazole interaction: a case report, Arch Dermatol, 132, 350, 10.1001/archderm.132.3.350 Jensen, 1987, Exacerbation of cyclosporine toxicity by concomitant administration of erythromycin, Transplantation, 43, 263, 10.1097/00007890-198702000-00020 Spicer, 1997, The mechanism of cyclosporine toxicity induced by clarithromycin, Br J Clin Pharmacol, 43, 194, 10.1046/j.1365-2125.1997.54310.x Lampen, 1995, Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability, Drug Metab Dispos, 23, 1315 Gomez, 1995, The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine, Clin Pharmacol Ther, 58, 15, 10.1016/0009-9236(95)90067-5 Floren, 1997, Tacrolimus oral bioavailability doubles with coadministration of ketoconazole, Clin Pharmacol Ther, 62, 41, 10.1016/S0009-9236(97)90150-8 Soltero, 2003, Coadministration of tacrolimus and ketoconazole in renal transplant recipients: cost analysis and review of metabolic effects, Transplant Proc, 35, 1319, 10.1016/S0041-1345(03)00450-0 Vasquez, 2001, Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients, Clin Transplant, 15, 95, 10.1034/j.1399-0012.2001.150203.x Bussey, 1985, Warfarin-erythromycin interaction, Arch Intern Med, 145, 1736, 10.1001/archinte.1985.00360090212038 Hassell, 1985, Suspected interaction: warfarin and erythromycin, South Med J, 78, 1015, 10.1097/00007611-198508000-00037 Bachmann, 1984, The effect of erythromycin on the disposition kinetics of warfarin, Pharmacology, 28, 171, 10.1159/000137958 Recker, 1997, Potential interaction between clarithromycin and warfarin, Ann Pharmacother, 31, 996, 10.1177/106002809703100907 Oberg, 1998, Delayed elevation of international normalized ratio with concurrent clarithromycin and warfarin therapy, Pharmacotherapy, 18, 386 Black, 1996, Warfarinfluconazole, part II: a metabolically based drug interaction: in vivo studies, Drug Metab Dispos, 24, 422 Berrettini, 1986, A case of erythromycin-induced carbamazepine toxicity, J Clin Psychiatry, 47, 147 Albani, 1993, Clarithromycin-carbamazepine interaction: a case report, Epilepsia, 34, 161, 10.1111/j.1528-1157.1993.tb02391.x O’Connor, 1994, Clarithromycin-carbamazepine interaction in a clinical setting, J Am Board Fam Pract, 7, 489 Wong YY Ludden, 1983, Effect of erythromycin on carbamazepine kinetics, Clin Pharmacol Ther, 33, 460, 10.1038/clpt.1983.62 Miles, 1989, Erythromycin effects on multiple-dose carbamazepine kinetics, Ther Drug Monit, 11, 47, 10.1097/00007691-198901000-00010 Spina, 1997, Elevation of plasma carbamazepine concentrations by ketoconazole in patients with epilepsy, Ther Drug Monit, 19, 535, 10.1097/00007691-199710000-00009 Nair, 1999, Potential fluconazole-induced carbamazepine toxicity, Ann Pharmacother, 33, 790, 10.1345/aph.18261 Finch, 2002, Fluconazole-carbamazepine interaction, South Med J, 95, 1099, 10.1097/00007611-200295090-00035 Tenenbein, 1989, Theophylline toxicity due to drug interaction, J Emerg Med, 7, 249, 10.1016/0736-4679(89)90355-7 Paulsen, 1987, The interaction of erythromycin with theophylline, Eur J Clin Pharmacol, 32, 493, 10.1007/BF00637676 Wiggins, 1986, Elevated serum theophylline concentration following cessation of erythromycin treatment, Eur J Respir Dis, 68, 298 Richards, 1985, Theophylline-associated seizures in children, Ann Allergy, 54, 276 Iliopoulou, 1982, Pharmacokinetic interaction between theophylline and erythromycin, Br J Clin Pharmacol, 14, 495, 10.1111/j.1365-2125.1982.tb02018.x Tjia, 1996, Theophylline metabolism in human liver microsomes: inhibition studies, J Pharmacol Exp Ther, 276, 912 Fleischmann, 2001, Topical and systemic antifungal and antiviral agents, 69